Systematic review evaluates current and emerging therapies for Alzheimer's disease, indicating future management implications.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide. Despite extensive research, effective disease-modifying therapies remain limited. This systematic review evaluates current and emerging therapeutic strategies for AD, including symptomatic pharmacological treatments, disease-modifying approaches targeting amyloid and tau pathology, and novel interventions such as gene therapy, stem cell therapy, and nanotechnology-based drug delivery systems. A structured literature search (2020–2025) was conducted across major databases. Findings suggest that while conventional therapies provide symptomatic relief, recently approved monoclonal antibodies demonstrate only modest clinical benefits. Emerging multi-target strategies and early intervention approaches hold promise for future management. However, challenges such as late diagnosis, blood–brain barrier limitations, and clinical trial failures persist.
No takes yet. Share an insight, caveat, or question.
2Sreenu Thalla *1Guduri Sri Padmavathi Pravallika (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: